Literature DB >> 6387061

Continuous infusion chemotherapy: a critical review.

N J Vogelzang.   

Abstract

With the development of reliable drug pumps and safe long-term venous access catheters, the continuous infusion of chemotherapeutic agents has become clinically feasible. The available studies on infusion therapy with 37 antineoplastic drugs are analyzed. With the majority of agents, infusion studies have either not been performed or the completed studies have failed to demonstrate improved effectiveness over bolus therapy. In some continuous infusion studies, effectiveness has been retained but with no apparent improvement in the therapeutic index. Several other drugs such as bleomycin, cytosine arabinoside, and doxorubicin have apparent improvement in the therapeutic index when given as a continuous infusion. The improved therapeutic index of the fluorinated pyrimidines when given via continuous infusion must be explored in randomized controlled studies using malignancies other than colorectal cancer. The cost effectiveness of such studies must be carefully assessed. Since this method of administration of chemotherapeutic agents offers the potential for less toxicity and retained antineoplastic effect, such investigations are highly desirable for improved patient care.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6387061     DOI: 10.1200/JCO.1984.2.11.1289

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  18 in total

Review 1.  Adverse effects of cancer chemotherapy. An overview of techniques for avoidance/minimisation.

Authors:  M Nicolson; R C Leonard
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

2.  Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective.

Authors:  Koji Takeda
Journal:  Ther Adv Med Oncol       Date:  2013-09       Impact factor: 8.168

3.  Suitability of cisplatin solutions for 14-day continuous infusion by ambulatory pump.

Authors:  M Hrubisko; A T Mc Gown; J A Prendiville; J A Radford; N Thatcher; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 4.  Continuous infusion of chemotherapy: focus on 5-fluorouracil and fluorodeoxyuridine.

Authors:  R L Poorter; P J Bakker; C H Veenhof
Journal:  Pharm World Sci       Date:  1998-04

5.  Tegafur and 5-fluorouracil pelvic tissue concentrations in rectal cancer patients receiving preoperative chemoradiation.

Authors:  F A Calvo; A Aldaz; L Zufía; D de la Mata; J Serrano; R García; J A Arranz; A Alvarado; J Giráldez
Journal:  Clin Transl Oncol       Date:  2006-07       Impact factor: 3.405

Review 6.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 7.  Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: a review.

Authors:  J Greidanus; P H Willemse; D R Uges; E T Oremus; Z J De Langen; E G De Vries
Journal:  Pharm Weekbl Sci       Date:  1988-12-09

8.  Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine.

Authors:  H J Keizer; E A De Bruijn; U R Tjaden; E De Clercq
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

9.  Salivary passage of 5-fluorouracil during continuous infusion.

Authors:  G Milano; A Thyss; J Santini; M Frenay; E Francois; M Schneider; F Demard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 10.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.